FY2025 Earnings Forecast for OKUR Issued By Lifesci Capital

OnKure Therapeutics (NASDAQ:OKUR) – Analysts at Lifesci Capital issued their FY2025 earnings estimates for shares of OnKure Therapeutics in a report issued on Tuesday, March 11th. Lifesci Capital analyst S. Slutsky expects that the company will earn ($5.14) per share for the year. The consensus estimate for OnKure Therapeutics’ current full-year earnings is ($4.05) per share.

OKUR has been the topic of several other research reports. Leerink Partners started coverage on OnKure Therapeutics in a research report on Thursday, December 5th. They set an “outperform” rating and a $33.00 price target on the stock. Leerink Partnrs upgraded shares of OnKure Therapeutics to a “strong-buy” rating in a research report on Thursday, December 5th. Finally, Oppenheimer reduced their price target on shares of OnKure Therapeutics from $35.00 to $30.00 and set an “outperform” rating for the company in a research report on Tuesday. Three investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $34.33.

OnKure Therapeutics Price Performance

OnKure Therapeutics stock opened at $4.61 on Thursday. The stock has a market cap of $15.41 million, a P/E ratio of -0.38 and a beta of 0.28. OnKure Therapeutics has a fifty-two week low of $4.45 and a fifty-two week high of $20.00. The firm has a 50-day moving average price of $5.73.

OnKure Therapeutics (NASDAQ:OKUR) last announced its quarterly earnings results on Monday, March 10th. The company reported ($1.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.86) by ($0.51).

Institutional Trading of OnKure Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. Acorn Capital Advisors LLC acquired a new position in shares of OnKure Therapeutics in the fourth quarter valued at approximately $12,381,000. Geode Capital Management LLC purchased a new position in OnKure Therapeutics in the 4th quarter valued at $659,000. Boothbay Fund Management LLC purchased a new position in OnKure Therapeutics in the 4th quarter valued at $671,000. Samsara BioCapital LLC acquired a new position in OnKure Therapeutics in the 4th quarter valued at $7,088,000. Finally, XTX Topco Ltd purchased a new position in OnKure Therapeutics during the 4th quarter worth $160,000. 90.98% of the stock is owned by institutional investors and hedge funds.

OnKure Therapeutics Company Profile

OnKure Therapeutics, Inc engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer.